Defining and Understanding Adaptive Resistance in Cancer Immunotherapy
- 1 August 2018
- journal article
- review article
- Published by Elsevier BV in Trends in Immunology
- Vol. 39 (8), 624-631
- https://doi.org/10.1016/j.it.2018.05.001
Abstract
No abstract availableKeywords
Funding Information
- NIH (P50 CA196530, P30 CA16359)
This publication has 54 references indexed in Scilit:
- Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)Journal of Clinical Oncology, 2017
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial CarcinomaJAMA Oncology, 2017
- Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung CancerClinical Cancer Research, 2017
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinationsScience Translational Medicine, 2016
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunityNature, 2015
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature, 2014
- Immune infiltration in human tumors: a prognostic factor that should not be ignoredOncogene, 2009
- Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impairedBlood, 2009
- Effector Memory T Cells, Early Metastasis, and Survival in Colorectal CancerThe New England Journal of Medicine, 2005
- Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosisJournal of Neuroimmunology, 2004